▶ video
Novartis-Avidity at $12B: One Filing, One Win, One Miss
Six months after closing the $72/share Avidity buy: del-zota sits under FDA priority review, del-brax won Phase 1/2, and del-desiran failed HARBOR — NVS fell 13.9%.
Topic
#rare-disease
1 post